货号:A148639 同义名:
恩替卡韦一水合物
/ BMS200475 monohydrate; SQ34676 monohydrate
Entecavir Monohydrate是一种鸟苷类似物,是乙肝病毒的逆转录酶抑制剂,在 HepG2 细胞中的 EC50 为 3.75 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
50μL*10mM(DMSO) | ¥99.00随货¥69 | 咨询 | |
100μL*10mM(DMSO) | ¥139.00随货¥99 | 咨询 | |
250μL*10mM(DMSO) | ¥259.00随货¥189 | 咨询 | |
500μL*10mM(DMSO) | ¥369.00随货¥259 | 咨询 | |
10mM*1mL(DMSO) | ¥501.00 | 咨询 | |
1mg | ¥207.00 | 咨询 | |
5mg | ¥455.00 | 咨询 | |
10mg | ¥553.00 | 咨询 | |
50mg | ¥1448.00 | 咨询 | |
100mg | ¥2100.00 | 咨询 |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Entecavir (ETV) Monohydrate is a first-line therapy for chronic hepatitis B virus (HBV), demonstrating potent suppression of HBV DNA and a high barrier to viral resistance[3]. Entecavir, a new deoxyguanosine analog, represents a third agent within the nucleoside/nucleotide HBV polymerase inhibitor class with distinct advantages over lamivudine and adefovir dipivoxil: it has a three-step mechanism of action, is the most potent inhibitor of HBV DNA polymerase, is not associated with any major adverse effects, and has a limited potential for resistance. In phase II and III clinical trials, entecavir was found to be superior to lamivudine for all primary endpoints evaluated in both nucleoside-naïve and lamivudine-resistant patients. Entecavir was effective in both HBeAg-positive and HBeAg-negative nucleoside-naïve patients[4]. In chronic hepatitis B patients experiencing clevudine-induced myopathy, switching to entecavir 0.5 mg per day showed a resolution of myopathy and adequate viral suppression[5]. Entecavir (ETV) resistance of hepatitis B virus (HBV) conventionally requires rt184, 202, or 250 mutations plus lamivudine-resistance mutation (rtM204V/I ± L180M)[6]. |
计算器 | ||||
存储液制备 | ![]() | 1mg | 5mg | 10mg |
1 mM 5 mM 10 mM | 3.39mL 0.68mL 0.34mL | 16.93mL 3.39mL 1.69mL | 33.87mL 6.77mL 3.39mL |
CAS号 | 209216-23-9 |
分子式 | C12H17N5O4 |
分子量 | 295.29 |
SMILES Code | O=C1NC(N)=NC2=C1N=CN2[C@@H]3C([C@H](CO)[C@@H](O)C3)=C.[H]O[H] |
MDL No. | MFCD09754448 |
别名 | 恩替卡韦一水合物 ;BMS200475 monohydrate; SQ34676 monohydrate; SQ 34,676; BMS 200475; Entecavir(hydrate); Entecavir Hydrate; Entecavir(monohydrate) |
运输 | 蓝冰 |
InChI Key | YXPVEXCTPGULBZ-WQYNNSOESA-N |
Pubchem ID | 135526609 |
存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
溶解方案 | DMSO: 50 mg/mL(169.32 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO H2O: 2.5 mg/mL(8.47 mM) 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|